Cancer
Topoisomerase inhibitors (etoposide, irinotecan)
Drugs that trap DNA-cutting enzymes on DNA: etoposide (topoisomerase II) in testicular tumours and small cell lung cancer; irinotecan (topoisomerase I) in colorectal cancer.
Mechanism of action
- Topoisomerases cut DNA to relieve the strain of unwinding and then reseal it.
- Etoposide stabilises the topoisomerase II–DNA complex, leaving double-strand breaks; it acts in S and G2 phases.
- Irinotecan (via its metabolite SN-38) and topotecan trap topoisomerase I, leaving single-strand breaks that become lethal at replication.
Molecular targets
- Topoisomerase II: Poison (etoposide)
- Topoisomerase I: Poison (irinotecan, topotecan)
Drugs in Topoisomerase inhibitors (etoposide, irinotecan)
Topoisomerase II inhibitor
- Etoposide (In BEP and EP regimens.)
Topoisomerase I inhibitors (camptothecins)
- Irinotecan (Prodrug; FOLFIRI.)
- Topotecan
Therapeutic uses
- Testicular germ cell tumours, including seminoma (etoposide with cisplatin)
- Small cell lung cancer (etoposide with a platinum drug)
- Metastatic colorectal cancer (irinotecan with a fluoropyrimidine)
Diseases it treats
Adverse effects
- Myelosuppression
- Severe diarrhoea, early (cholinergic) and late (irinotecan)
- Hair loss and mucositis
- Secondary leukaemia (etoposide)
Contraindications by condition
- Gilbert syndrome or low UGT1A1 activity (irinotecan) (Use with care): SN-38 is inactivated by UGT1A1: low activity causes severe neutropenia and diarrhoea.
- Ulcerative colitis (Use with care): Its diarrhoea can be severe.
- Pregnancy (Contraindicated): Cytotoxic to the fetus.
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 35, Anticancer Drugs, Topoisomerase inhibitors
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, Topoisomerase inhibitors
Educational reference. Not medical advice, diagnosis or treatment.